Observe the effect os radiotherapy plus or not plus endostar in the treatment of brain metastasis in NSCLC
The investigators will observe the time controlled by the brain lesion after the test and the total survival time of the patients. Meanwhile, during each follow-up, the investigators will extract cerebrospinal fluid for genomic analysis of cerebrospinal fluid
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
50
Union Hospital
Wuhan, Hubei, China
RECRUITINGProgression Free Survival (PFS)
the time from the start of treatment to the progression of the brain metastases, in months
Time frame: From date of randomization until the date of first documented progression of brain lesions, and the maximum evaluation time is 36 months
Overall survival （OS）
the total survival time of the patient from the start of treatment
Time frame: From date of randomization until the date of death, assessed up to 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.